Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-GPRC5D/anti-CD19 CAR T cells

A preparation of T lymphocytes engineered to express chimeric antigen receptor(s) (CARs) targeting the human tumor-associated antigens (TAAs) G-protein coupled receptor family C group 5 member D (GPRC5D) and CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPRC5D/anti-CD19 CAR T cells specifically and simultaneously target and bind to tumor cells expressing GPRC5D and/or CD19. This induces selective toxicity in tumor cells that express GPRC5D and/or CD19. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies.
Synonym:anti-CD19/anti-GPRC5D CAR T cells
anti-GPRC5D-CD19-CAR-T cells
anti-GPRC5D/CD19 CAR T cells
GPRC5D-CD19 CAR T cells
Search NCI's Drug Dictionary